Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 620

1.

ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers.

Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, Zielinski C, Piccart MJ, Bogaerts J, Tabernero J, Latino NJ, de Vries EG.

ESMO Open. 2016 Oct 18;1(5):e000100. Review.

PMID:
27900206
2.

Papaverine-sensitive phosphodiesterase activity is measured in bovine spermatozoa.

Bergeron A, Hébert A, Guillemette C, Laroche A, Poulin MP, Aragon JP, Leclerc P, Sullivan R, Blondin P, Vigneault C, Richard FJ.

Andrology. 2016 Nov 16. doi: 10.1111/andr.12290. [Epub ahead of print]

PMID:
27860455
3.

An assessment of the barriers to accessing the Basic Package of Health Services (BPHS) in Afghanistan: was the BPHS a success?

Frost A, Wilkinson M, Boyle P, Patel P, Sullivan R.

Global Health. 2016 Nov 15;12(1):71. Review.

4.

ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016.

Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El-Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G, Awada A, Banerjee S, Bhatia S, Bogaerts J, Buckner J, Cardoso F, Casali P, Chu E, Close JL, Coiffier B, Connolly R, Coupland S, De Petris L, De Santis M, de Vries EG, Dizon DS, Duff J, Duska LR, Eniu A, Ernstoff M, Felip E, Fey MF, Gilbert J, Girard N, Glaudemans AW, Gopalan PK, Grothey A, Hahn SM, Hanna D, Herold C, Herrstedt J, Homicsko K, Jones DV Jr, Jost L, Keilholz U, Khan S, Kiss A, Köhne CH, Kunstfeld R, Lenz HJ, Lichtman S, Licitra L, Lion T, Litière S, Liu L, Loehrer PJ, Markham MJ, Markman B, Mayerhoefer M, Meran JG, Michielin O, Moser EC, Mountzios G, Moynihan T, Nielsen T, Ohe Y, Öberg K, Palumbo A, Peccatori FA, Pfeilstöcker M, Raut C, Remick SC, Robson M, Rutkowski P, Salgado R, Schapira L, Schernhammer E, Schlumberger M, Schmoll HJ, Schnipper L, Sessa C, Shapiro CL, Steele J, Sternberg CN, Stiefel F, Strasser F, Stupp R, Sullivan R, Tabernero J, Travado L, Verheij M, Voest E, Vokes E, Von Roenn J, Weber JS, Wildiers H, Yarden Y.

ESMO Open. 2016 Sep 29;1(5):e000097. Review.

5.

Pharmacodynamic study of the oral hedgehog pathway inhibitor, vismodegib, in patients with metastatic castration-resistant prostate cancer.

Maughan BL, Suzman DL, Luber B, Wang H, Glavaris S, Hughes R, Sullivan R, Harb R, Boudadi K, Paller C, Eisenberger M, Demarzo A, Ross A, Antonarakis ES.

Cancer Chemother Pharmacol. 2016 Dec;78(6):1297-1304.

PMID:
27826729
6.

The global burden of women's cancers: a grand challenge in global health.

Ginsburg O, Bray F, Coleman MP, Vanderpuye V, Eniu A, Kotha SR, Sarker M, Huong TT, Allemani C, Dvaladze A, Gralow J, Yeates K, Taylor C, Oomman N, Krishnan S, Sullivan R, Kombe D, Blas MM, Parham G, Kassami N, Conteh L.

Lancet. 2016 Nov 1. pii: S0140-6736(16)31392-7. doi: 10.1016/S0140-6736(16)31392-7. [Epub ahead of print] Review.

PMID:
27814965
7.

Changing global policy to deliver safe, equitable, and affordable care for women's cancers.

Ginsburg O, Badwe R, Boyle P, Derricks G, Dare A, Evans T, Eniu A, Jimenez J, Kutluk T, Lopes G, Mohammed SI, Qiao YL, Rashid SF, Summers D, Sarfati D, Temmerman M, Trimble EL, Padela AI, Aggarwal A, Sullivan R.

Lancet. 2016 Nov 1. pii: S0140-6736(16)31393-9. doi: 10.1016/S0140-6736(16)31393-9. [Epub ahead of print] Review.

PMID:
27814964
8.

Novel mutations in LRP6 highlight the role of WNT signaling in tooth agenesis.

Ockeloen CW, Khandelwal KD, Dreesen K, Ludwig KU, Sullivan R, van Rooij IA, Thonissen M, Swinnen S, Phan M, Conte F, Ishorst N, Gilissen C, Roa Fuentes L, van de Vorst M, Henkes A, Steehouwer M, van Beusekom E, Bloemen M, Vankeirsbilck B, Bergé S, Hens G, Schoenaers J, Vander Poorten V, Roosenboom J, Verdonck A, Devriendt K, Roeleveldt N, Jhangiani SN, Vissers LE, Lupski JR, de Ligt J, Von den Hoff JW, Pfundt R, Brunner HG, Zhou H, Dixon J, Mangold E, van Bokhoven H, Dixon MJ, Kleefstra T, Hoischen A, Carels CE.

Genet Med. 2016 Nov;18(11):1158-1162. doi: 10.1038/gim.2016.10.

9.

Reply to the letter to the editor 'Utilisation of the ESMO-MCBS in practice of HTA' by Wild et al.

Cherny NI, Sullivan R, Dafni U, Bogaerts J, Kerst JM, Zielinski C, Piccart MJ, de Vries EG.

Ann Oncol. 2016 Nov;27(11):2136-2137. No abstract available.

PMID:
27573563
10.

Short-term breast cancer survival in relation to ethnicity, stage, grade and receptor status: national cohort study in England.

Møller H, Henson K, Lüchtenborg M, Broggio J, Charman J, Coupland VH, Davies E, Jack RH, Sullivan R, Vedsted P, Horgan K, Pearce N, Purushotham A.

Br J Cancer. 2016 Nov 22;115(11):1408-1415. doi: 10.1038/bjc.2016.335.

PMID:
27780193
11.

Do Contemporary Randomized Controlled Trials Meet ESMO Thresholds for Meaningful Clinical Benefit?

Del Paggio JC, Azariah B, Sullivan R, Hopman WM, James FV, Roshni S, Tannock IF, Booth CM.

Ann Oncol. 2016 Oct 13. pii: mdw538. [Epub ahead of print]

PMID:
27742650
12.

Eradicating polio in Pakistan: an analysis of the challenges and solutions to this security and health issue.

Hussain SF, Boyle P, Patel P, Sullivan R.

Global Health. 2016 Oct 12;12(1):63. Review.

13.

Bullying Prevention: a Summary of the Report of the National Academies of Sciences, Engineering, and Medicine : Committee on the Biological and Psychosocial Effects of Peer Victimization: Lessons for Bullying Prevention.

Flannery DJ, Todres J, Bradshaw CP, Amar AF, Graham S, Hatzenbuehler M, Masiello M, Moreno M, Sullivan R, Vaillancourt T, Le Menestrel SM, Rivara F.

Prev Sci. 2016 Nov;17(8):1044-1053.

PMID:
27722816
14.

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).

Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, Zielinski C, de Vries EG, Piccart MJ.

Ann Oncol. 2016 Sep 7. pii: mdw258. [Epub ahead of print] No abstract available.

PMID:
27604385
15.

Characterization of cAMP-phosphodiesterase activity in bovine seminal plasma.

Bergeron A, Aragon JP, Guillemette C, Hébert A, Sullivan R, Blondin P, Richard FJ.

Andrology. 2016 Aug 27. doi: 10.1111/andr.12267. [Epub ahead of print]

PMID:
27565610
16.

Cancer in Europe: Death sentence or life sentence?

Liu L, O'Donnell P, Sullivan R, Katalinic A, Moser L, de Boer A, Meunier F; Scientific and Organizing Committee..

Eur J Cancer. 2016 Sep;65:150-5. doi: 10.1016/j.ejca.2016.07.007.

PMID:
27498140
17.

Economic burden of malignant blood disorders across Europe: a population-based cost analysis.

Burns R, Leal J, Sullivan R, Luengo-Fernandez R.

Lancet Haematol. 2016 Aug;3(8):e362-70. doi: 10.1016/S2352-3026(16)30062-X.

PMID:
27476787
18.

ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe.

Cherny N, Sullivan R, Torode J, Saar M, Eniu A.

Ann Oncol. 2016 Aug;27(8):1423-43. doi: 10.1093/annonc/mdw213.

PMID:
27457309
19.

Medical intelligence, security and global health: the foundations of a new health agenda.

Bowsher G, Milner C, Sullivan R.

J R Soc Med. 2016 Jul;109(7):269-73. doi: 10.1177/0141076816656483. Review.

PMID:
27385714
20.

Patient Mobility for Elective Secondary Health Care Services in Response to Patient Choice Policies: A Systematic Review.

Aggarwal A, Lewis D, Mason M, Sullivan R, van der Meulen J.

Med Care Res Rev. 2016 Jun 28. pii: 1077558716654631. [Epub ahead of print]

PMID:
27357394
Items per page

Supplemental Content

Loading ...
Support Center